Our world-class clinical trials and biomedical research focuses on liver and respiratory disease, and oncology.
These diseases represent areas of significant clinical need, and also impact veterans at higher rates.
We maintain close relationships with research, government, not-for-profit and ex-service organisations to support the advancement of research and innovation.
run at GMR in 2024-25
(about 6 million people) are affected by fatty liver disease
in the number of NTM cases each year
We conducted leading clinical trials in liver and respiratory illnesses, and oncology.
We have 40-50 active national and international clinical trials at any one time, and we are a world-first recruiter and highest recruiter for many clinical trials.
One in four adults has, or will develop, fatty liver disease—that’s six million Australians.
We are fighting the rising global epidemic of fatty liver disease through our innovative liver research. We are also working to tackle liver cancer, which is not only rising in Australia, but has only a 23% five-year survival rate.
Our liver research is led by GMR’s Director of Research, Professor Darrell Crawford.
We focus on research into pulmonary nontuberculous mycobacterial (NTM) infections and bronchiectasis, a common chronic lung disease.
Both conditions are closely related and are increasing in prevalence in Australia.
Our pioneering work in this area is led by Professor Rachel Thomson.
